{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:26:07Z","timestamp":1794119167333,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002927","name":"Addenbrooke's Charitable Trust, Cambridge University Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002927","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glomerulonephritis (GN) accounts for 20%\u201325% of the causes of chronic and end-stage kidney disease. The evolving treatment landscape with new targeted immunosuppressants has highlighted the unmet need for equity of access to specialist GN services. Regional networks and multidisciplinary team meetings (MDTs) provide access to clinical expertise, high-cost drugs (HCDs) and clinical trials, facilitating collaborative decision-making and optimal use of therapeutics to improve patient outcomes. Launched in May 2023 in the East of England (EoE), the Eastern Network Kidney Inflammatory Disease MDT (ENKID) provides a regional MDT framework designed to improve access to specialist expertise and HCDs- areas identified as lacking for 59% of nephrologists in a 2024 UK GN service survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ENKID is led by the specialist vasculitis, lupus and primary GN service in Cambridge. A database build allows secure standardised data collection including referral indications and treatment decisions during fortnightly virtual regional MDTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over 24 months, 229 discussions were conducted for 198 patients in 43 ENKID MDTs, averaging 15 attendees from 6 centres per meeting. Patients were referred for both clinical complexity and HCD use in 46% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009106), solely HCD access in 42% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200996) and for clinical complexity alone in 12% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927). Clinical trial eligibility was an additional reason in 9% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920). Diagnoses discussed were ANCA-associated vasculitis (33%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200965), membranous nephropathy (18%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200935), IgA nephropathy (19%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200938), lupus nephritis (15%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929), minimal change disease\/focal segmental glomerulosclerosis (7%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914), rarer diseases (5%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) and diagnostic uncertainty (3%,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097). Including rituximab, a HCD was endorsed in 71% and alternative treatment recommended in 29% of referrals for HCD discussions. A wide geographical distribution of referrals was observed and facilitated widespread access to HCDs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ENKID regional MDT addresses the increasing demand for specialist advice for patients with complex and rare kidney diseases. High attendance and case load underscore the need for this service, aligning with the UK government\u2019s mandate for rare autoimmune disease. Integration of this MDT within the EoE NHS England renal network structure, providing governance, education and HCD access, serves as an exemplar for improving GN patient care and accessibility of UK services.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04849-6","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:46:18Z","timestamp":1774680378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The UK Eastern Network for Kidney Inflammatory Disease (ENKID) MDT at 24 months: advancing access to high-cost drugs, clinical trials, and complex case management in renal autoimmune diseases"],"prefix":"10.1186","volume":"27","author":[{"given":"Lucy","family":"Francis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Kanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Suchanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Willcocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Loudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Morlidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"July Da Silva","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Laforteza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Jeevaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances C.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R. W.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of ENKID","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"4849_CR1","unstructured":"ZS Associates. Kidney disease: a UK public health emergency. Kidney Res UK. 2023. https:\/\/www.kidneyresearchuk.org\/wp-content\/uploads\/2023\/06\/Economics-of-Kidney-Disease-full-report_accessible.pdf."},{"key":"4849_CR2","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021. PMID: 34556256.","DOI":"10.1016\/j.kint.2021.05.021"},{"key":"4849_CR3","unstructured":"National Institute for Health and Care Excellence. Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis: technology appraisal guidance. [NICE TA 825]. 2022. https:\/\/www.nice.org.uk\/guidance\/ta825\/resources\/avacopan-for-treating-severe-active-granulomatosis-with-polyangiitis-or-microscopic-polyangiitis-pdf-82613372500933."},{"key":"4849_CR4","unstructured":"National Institute for Health and Care Excellence. Voclosporin with mycophenolate mofetil for treating lupus nephritis: technology appraisal guidance. [NICE TA 882]. 2023. https:\/\/www.nice.org.uk\/guidance\/ta882\/resources\/voclosporin-with-mycophenolate-mofetil-for-treating-lupus-nephritis-pdf-82613730259141."},{"key":"4849_CR5","unstructured":"National Institute for Health and Care Excellence. Belimumab for treating active autoantibody-positive systemic lupus erythematosus: technology appraisal guidance.e [NICE TA 752]. 2021. https:\/\/www.nice.org.uk\/guidance\/ta752\/resources\/belimumab-for-treating-active-autoantibodypositive-systemic-lupus-erythematosus-pdf-82611372078277."},{"key":"4849_CR6","unstructured":"National Institute for Health and Care Excellence. Targeted-release budesonide for treating primary IgA nephropathy: technology appraisal guidance. [NICE TA 937]. 2023. https:\/\/www.nice.org.uk\/guidance\/ta937\/resources\/targetedrelease-budesonide-for-treating-primary-iga-nephropathy-pdf-82615613108677."},{"key":"4849_CR7","unstructured":"National Institute for Health and Care Excellence. Sparsentan for treating primary IgA nephropathy: technology appraisal guidance. [NICE TA 1074]. 2025. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1074\/resources\/sparsentan-for-treating-primary-iga-nephropathy-pdf-2973528636559045."},{"key":"4849_CR8","unstructured":"ClinicalTrials.gov. Phase III study assessing the efficacy and safety of pegcetacoplan in patients with c3 glomerulopathy or immune-complex membranoproliferative glomerulonephritis (VALIANT). National Library of Medicine. https:\/\/clinicaltrials.gov\/study\/NCT05067127."},{"key":"4849_CR9","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of iptacopan in patients with C3 Glomerulopathy (APPEAR-C3G). National Library of Medicine. https:\/\/www.clinicaltrials.gov\/study\/NCT04817618."},{"issue":"15","key":"4849_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Mart\u00ednez G, Santill\u00e1n AEZ, et al. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. N Engl J Med. 2025;392(15):1471\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2410965. PubMed PMID:39927615.","journal-title":"N Engl J Med"},{"key":"4849_CR11","unstructured":"Department of Health and Social Care. UK Rare Diseases Framework. Department of Health and Social Care. 2021. https:\/\/assets.publishing.service.gov.uk\/media\/5ff781138fa8f5640335254e\/the-UK-rare-diseases-framework.pdf."},{"key":"4849_CR12","unstructured":"Lipkin G, McKane W. Renal medicine: GIRFT Programme national specialty report. Getting It Right First Time. 2021. https:\/\/gettingitrightfirsttime.co.uk\/wp-content\/uploads\/2021\/09\/Renal-Medicine-Sept21k.pdf."},{"key":"4849_CR13","doi-asserted-by":"publisher","unstructured":"Hollick RJ, James WRG, Nicoll A, Locock L, Black C, Dhaun N, Egan AC, Fluck N, Laidlaw L, Lanyon PC, Little MA, Luqmani RA, Moir L, McBain M, Basu N. Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study. Lancet Rheumatol. 2024;6(6):e361-e373. https:\/\/doi.org\/10.1016\/S2665-9913(24)00082-1. PMID: 38782514.","DOI":"10.1016\/S2665-9913(24)00082-1"},{"key":"4849_CR14","doi-asserted-by":"publisher","unstructured":"Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, Ramirez AJ. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010;340:c951. https:\/\/doi.org\/10.1136\/bmj.c951. PMID: 20332315.","DOI":"10.1136\/bmj.c951"},{"key":"4849_CR15","unstructured":"Sinha S. Renal service transformation programme. https:\/\/nhsbtdbe.blob.core.windows.net\/umbraco-assets-corp\/30040\/renal-services-transformation-programme-s-sinha.pdf."},{"key":"4849_CR16","unstructured":"Office for National Statistics. Population estimates for the United Kingdom, England and Wales, Scotland and Northern Ireland, mid-2019. Newport: ONS. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland."},{"key":"4849_CR17","unstructured":"British Society for Rheumatology. Best practice case study: videoconferencing in the East of England. British society for rheumatology. https:\/\/www.rheumatology.org.uk\/news\/details\/Best-Practice-case-study-videoconferencing-in-the-East-of-England."},{"key":"4849_CR18","unstructured":"Rare Autoimmune Rheumatic Disease Alliance (RAIRDA). Resetting the balance: improving care and outcomes for rare autoimmune rheumatic diseases. RAIRDA. 2022. https:\/\/rairda.org\/wp-content\/uploads\/2022\/11\/Resetting-the-Balance-Report-RAIRDA.pdf."},{"key":"4849_CR19","unstructured":"Rough E, Garratt K, Burnett H. Rare autoimmune rheumatic diseases. House of commons library. Number CDP-O167. 2024. https:\/\/researchbriefings.files.parliament.uk\/documents\/CDP-2024-0167\/CDP-2024-0167.pdf."},{"key":"4849_CR20","unstructured":"NHS England. Rare disease collaborative networks. NHS England. https:\/\/www.england.nhs.uk\/commissioning\/spec-services\/highly-spec-services\/rare-disease-collaborative-networks\/."},{"key":"4849_CR21","unstructured":"Health Education England. East of England. Living and working in the East of England: a guide to our workforce partnership areas. Health education England. https:\/\/heeoe.hee.nhs.uk\/sites\/default\/files\/docustore\/1413899772_pdvr_living_and_working_in_the_east_of_england.pdf."},{"key":"4849_CR22","unstructured":"Ministry of Housing. Communities & local government. English indices of deprivation 2019. https:\/\/imd-by-postcode.opendatacommunities.org\/imd\/2019."},{"key":"4849_CR23","unstructured":"ClinicalTrials.gov. A study to assess the efficacy and safety of ravulizumab in adults with immunoglobulin a nephropathy (I CAN-IgAN-302). Identifier: NCT06291376. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06291376."},{"key":"4849_CR24","doi-asserted-by":"publisher","unstructured":"Free ME. Emerging cell therapies in the vasculitis field. Rheumatology. 2025;64:i11\u2013i14. Available from: https:\/\/doi.org\/10.1093\/rheumatology\/keae518.","DOI":"10.1093\/rheumatology\/keae518"},{"issue":"8","key":"4849_CR25","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1093\/rheumatology\/keaf240","volume":"64","author":"K Biddle","year":"2025","unstructured":"Biddle K, Jade J, Wilson-Morkeh H, Adikari M, Al Yaghchi C, Anastasa Z, Basu N, Brogan P, Chanouzas D, Dass S, D\u2019Cruz D, Del Martinez M, Dhillon E, Ducker G, Griffin S, Hollick RJ, Jackson D, King C, Marlais M, Mason A, McAdoo S, Mewar D, Mooney J, Ntatsaki E, Pearce F, Rhodes B, Rupani H, Salama A, Siddiqui S, Smith R, Harper L, British Society for Rheumatology Guideline Steering Group. The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis. Rheumatology (Oxford). 2025;64(8):4470\u201394. https:\/\/doi.org\/10.1093\/rheumatology\/keaf240.","journal-title":"Rheumatology (Oxford)"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04849-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04849-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04849-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:02:41Z","timestamp":1781643761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04849-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4849"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04849-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided informed consent for case discussion and data entry at the ENKID multidisciplinary team meetings. The Cambridge University Hospitals NHS Foundation Trust Institutional Review Board determined that ethical approval was not required for this service evaluation (Project ID 7581), in accordance with UK NHS Research Ethics Committee guidelines (\n                      \n                      ). This work comprises retrospective data, and all treatment decisions were made before our evaluation. No patient outcome data and only limited demographic data are reported. This study was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Outside the scope of this work, L.F. has received honoraria from CSL Vifor and Addenbrooke\u2019s Charitable Trust. K.W.L had advisory board and consulting fees: Boehringer Ingelheim, CSL Vifor; honoraria for presentations: Astra Zeneca; support for attending meetings: Novartis. L.C.W. is an investigator in clinical trials sponsored by Chemocentryx, Rigel, Novartis and GSK. R.M.S has received research grants from Union Therapeutics, GlaxoSmithKline, LifeArc, Kidney Research UK and Addenbrooke\u2019s Charitable Trust. F.C.H has received contributions towards trials from Alexion Pharmaceuticals and Eli Lilly and Company and UK Research and Innovation; and towards research infrastructure from the UK National Institute for Health and Care Research and reports payment for weekend shifts for Clinical Investigators from Addenbrooke\u2019s Charitable Trust. D.R.W.J. has received research or educational grants from Chemocentryx, GSK, InflaRx, and Sanofi, and received consulting fees from Celgene, Chemocentryx, GSK, InflaRX and Insmed. R.B.J. has research grants from CSL Vifor and Roche, Honorarium from Roche, Consultancy from CSL Vifor. All other authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}